Latest Developments in Global Drug Delivery Devices Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Drug Delivery Devices Market

  • Medical Devices
  • May 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In January 2025, Phillips Medisize, a Molex company, completed the acquisition of Vectura Group Ltd., enhancing its inhalation drug delivery capabilities. This strategic move adds expertise in dry powder inhalers, metered dose inhalers, nasal inhalers, and nebulizers, broadening Phillips Medisize's portfolio in pharmaceutical device design and manufacturing
  • In January 2025, Nipro and Nemera announced the successful compatibility testing of Nemera's UniSpray device with Nipro's unit-dose microvials. This collaboration aims to enhance nasal drug delivery by combining Nipro's precision glass vials with Nemera's intuitive nasal spray device, offering a reliable solution for single-dose nasal medication administration
  • In October 2024, Aptar Pharma, a global leader in drug delivery systems, acquired all device technology assets from the proprietary portfolio of SipNose Nasal Delivery Systems, a company focused on intranasal delivery platforms for local, systemic, and central nervous system indications. The acquisition will expand Aptar Pharma’s patent product portfolio and support new product development
  • In February 2023, Innovation Zed, one of the leading key players, received the CE mark for its InsulCheck DOSE, a single-unit add-on device for insulin pen injectors
  • In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
  • In September 2022, Corium, Inc., a biopharmaceutical company, launched ADLARITY, a donepezil transdermal system in the U.S. for treating patients suffering from mild to severe Alzheimer’s
  • In August 2022, Baxter announced the U.S. FDA Clearance of the Novum IQ Syringe Infusion Pump with Dose IQ Safety Software. The Novum IQ Syringe infusion pumps precisely deliver small amounts of fluid at low rates, frequently in pediatric, neonatal or anesthesia care settings